Challenges in access to oncology medicines: Policies and practices across the OECD and the EU
With rapid advancements in oncology, even the wealthiest countries around the globe find it increasingly challenging to provide - and sustain - access to new medicines. Challenges include managing the uncertainty surrounding the extent of benefit of new treatments; complexities in determining the pr...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | , |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Paris
OECD Publishing
2020
|
| Schriftenreihe: | OECD Health Working Papers
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | With rapid advancements in oncology, even the wealthiest countries around the globe find it increasingly challenging to provide - and sustain - access to new medicines. Challenges include managing the uncertainty surrounding the extent of benefit of new treatments; complexities in determining the price and place in therapy of certain products; and the need to reconcile affordable, equitable access with spending efficiency and fiscal sustainability. Differences in timing of market entry and heterogeneity of coverage processes and policies contribute to inequity in access across the OECD and EU. Future policies and practices to promote sustainable access to oncology medicines will likely focus on improving affordability for patients and value-for-money for payers. An important element will be strengthening the evidence base, drawing on both clinical trial and "real world" evidence, and enhancing international collaboration and information sharing to improve countries' collective capacity to address clinical and economic uncertainties |
| Beschreibung: | 1 Online-Ressource (108 Seiten) |
| DOI: | 10.1787/4b2e9cb9-en |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV047937705 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 220413s2020 xx o|||| 00||| eng d | ||
| 024 | 7 | |a 10.1787/4b2e9cb9-en |2 doi | |
| 035 | |a (ZDB-13-SOC)061235563 | ||
| 035 | |a (OCoLC)1312692316 | ||
| 035 | |a (DE-599)BVBBV047937705 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-384 |a DE-91 |a DE-473 |a DE-824 |a DE-29 |a DE-739 |a DE-355 |a DE-20 |a DE-1028 |a DE-1049 |a DE-188 |a DE-521 |a DE-861 |a DE-898 |a DE-92 |a DE-573 |a DE-19 | ||
| 100 | 1 | |a Chapman, Suzannah |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Challenges in access to oncology medicines |b Policies and practices across the OECD and the EU |c Suzannah Chapman, Valérie Paris and Ruth Lopert |
| 264 | 1 | |a Paris |b OECD Publishing |c 2020 | |
| 300 | |a 1 Online-Ressource (108 Seiten) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a OECD Health Working Papers | |
| 520 | |a With rapid advancements in oncology, even the wealthiest countries around the globe find it increasingly challenging to provide - and sustain - access to new medicines. Challenges include managing the uncertainty surrounding the extent of benefit of new treatments; complexities in determining the price and place in therapy of certain products; and the need to reconcile affordable, equitable access with spending efficiency and fiscal sustainability. Differences in timing of market entry and heterogeneity of coverage processes and policies contribute to inequity in access across the OECD and EU. Future policies and practices to promote sustainable access to oncology medicines will likely focus on improving affordability for patients and value-for-money for payers. An important element will be strengthening the evidence base, drawing on both clinical trial and "real world" evidence, and enhancing international collaboration and information sharing to improve countries' collective capacity to address clinical and economic uncertainties | ||
| 650 | 4 | |a Social Issues/Migration/Health | |
| 700 | 1 | |a Paris, Valérie |4 ctb | |
| 700 | 1 | |a Lopert, Ruth |4 ctb | |
| 856 | 4 | 0 | |u https://doi.org/10.1787/4b2e9cb9-en |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ZDB-13-SOC | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-033319199 | |
Datensatz im Suchindex
| _version_ | 1818806147281321984 |
|---|---|
| adam_text | |
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Chapman, Suzannah |
| author2 | Paris, Valérie Lopert, Ruth |
| author2_role | ctb ctb |
| author2_variant | v p vp r l rl |
| author_facet | Chapman, Suzannah Paris, Valérie Lopert, Ruth |
| author_role | aut |
| author_sort | Chapman, Suzannah |
| author_variant | s c sc |
| building | Verbundindex |
| bvnumber | BV047937705 |
| collection | ZDB-13-SOC |
| ctrlnum | (ZDB-13-SOC)061235563 (OCoLC)1312692316 (DE-599)BVBBV047937705 |
| discipline | Wirtschaftswissenschaften |
| discipline_str_mv | Wirtschaftswissenschaften |
| doi_str_mv | 10.1787/4b2e9cb9-en |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000zc 4500</leader><controlfield tag="001">BV047937705</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">220413s2020 xx o|||| 00||| eng d</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/4b2e9cb9-en</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-13-SOC)061235563</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1312692316</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV047937705</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-384</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-1028</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-521</subfield><subfield code="a">DE-861</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Chapman, Suzannah</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Challenges in access to oncology medicines</subfield><subfield code="b">Policies and practices across the OECD and the EU</subfield><subfield code="c">Suzannah Chapman, Valérie Paris and Ruth Lopert</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (108 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Health Working Papers</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">With rapid advancements in oncology, even the wealthiest countries around the globe find it increasingly challenging to provide - and sustain - access to new medicines. Challenges include managing the uncertainty surrounding the extent of benefit of new treatments; complexities in determining the price and place in therapy of certain products; and the need to reconcile affordable, equitable access with spending efficiency and fiscal sustainability. Differences in timing of market entry and heterogeneity of coverage processes and policies contribute to inequity in access across the OECD and EU. Future policies and practices to promote sustainable access to oncology medicines will likely focus on improving affordability for patients and value-for-money for payers. An important element will be strengthening the evidence base, drawing on both clinical trial and "real world" evidence, and enhancing international collaboration and information sharing to improve countries' collective capacity to address clinical and economic uncertainties</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Issues/Migration/Health</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Paris, Valérie</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lopert, Ruth</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1787/4b2e9cb9-en</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033319199</subfield></datafield></record></collection> |
| id | DE-604.BV047937705 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T19:35:07Z |
| indexdate | 2024-12-18T19:05:09Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033319199 |
| oclc_num | 1312692316 |
| open_access_boolean | 1 |
| owner | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| owner_facet | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| physical | 1 Online-Ressource (108 Seiten) |
| psigel | ZDB-13-SOC |
| publishDate | 2020 |
| publishDateSearch | 2020 |
| publishDateSort | 2020 |
| publisher | OECD Publishing |
| record_format | marc |
| series2 | OECD Health Working Papers |
| spelling | Chapman, Suzannah Verfasser aut Challenges in access to oncology medicines Policies and practices across the OECD and the EU Suzannah Chapman, Valérie Paris and Ruth Lopert Paris OECD Publishing 2020 1 Online-Ressource (108 Seiten) txt rdacontent c rdamedia cr rdacarrier OECD Health Working Papers With rapid advancements in oncology, even the wealthiest countries around the globe find it increasingly challenging to provide - and sustain - access to new medicines. Challenges include managing the uncertainty surrounding the extent of benefit of new treatments; complexities in determining the price and place in therapy of certain products; and the need to reconcile affordable, equitable access with spending efficiency and fiscal sustainability. Differences in timing of market entry and heterogeneity of coverage processes and policies contribute to inequity in access across the OECD and EU. Future policies and practices to promote sustainable access to oncology medicines will likely focus on improving affordability for patients and value-for-money for payers. An important element will be strengthening the evidence base, drawing on both clinical trial and "real world" evidence, and enhancing international collaboration and information sharing to improve countries' collective capacity to address clinical and economic uncertainties Social Issues/Migration/Health Paris, Valérie ctb Lopert, Ruth ctb https://doi.org/10.1787/4b2e9cb9-en Verlag kostenfrei Volltext |
| spellingShingle | Chapman, Suzannah Challenges in access to oncology medicines Policies and practices across the OECD and the EU Social Issues/Migration/Health |
| title | Challenges in access to oncology medicines Policies and practices across the OECD and the EU |
| title_auth | Challenges in access to oncology medicines Policies and practices across the OECD and the EU |
| title_exact_search | Challenges in access to oncology medicines Policies and practices across the OECD and the EU |
| title_exact_search_txtP | Challenges in access to oncology medicines Policies and practices across the OECD and the EU |
| title_full | Challenges in access to oncology medicines Policies and practices across the OECD and the EU Suzannah Chapman, Valérie Paris and Ruth Lopert |
| title_fullStr | Challenges in access to oncology medicines Policies and practices across the OECD and the EU Suzannah Chapman, Valérie Paris and Ruth Lopert |
| title_full_unstemmed | Challenges in access to oncology medicines Policies and practices across the OECD and the EU Suzannah Chapman, Valérie Paris and Ruth Lopert |
| title_short | Challenges in access to oncology medicines |
| title_sort | challenges in access to oncology medicines policies and practices across the oecd and the eu |
| title_sub | Policies and practices across the OECD and the EU |
| topic | Social Issues/Migration/Health |
| topic_facet | Social Issues/Migration/Health |
| url | https://doi.org/10.1787/4b2e9cb9-en |
| work_keys_str_mv | AT chapmansuzannah challengesinaccesstooncologymedicinespoliciesandpracticesacrosstheoecdandtheeu AT parisvalerie challengesinaccesstooncologymedicinespoliciesandpracticesacrosstheoecdandtheeu AT lopertruth challengesinaccesstooncologymedicinespoliciesandpracticesacrosstheoecdandtheeu |